公众在互联网上能获取怎样的双膦酸盐治疗信息:一项编码内容与质量的描述性研究
常见益处为预防骨密度下降(77.1%的网站),常见副作用为胃肠道问题(66.1%)和颌骨坏死(58.6%);多数网站未量化益处(78.0%)或副作用(82.4%),补充与整合健康网站及药品诉讼网站更常偏向反对使用双膦酸盐(均P < .001),一般医学知识网站较其他网站更平衡(P = .023)。
要点
- 227个纳入网站中最常描述的益处是预防骨密度下降(77.1%)。
- 最常描述的副作用是胃肠道问题(66.1%)和颌骨坏死(58.6%)。
- 多数网站未量化益处(78.0%)或副作用(82.4%)。
核心结论
- 互联网上双膦酸盐信息的质量差异很大。
- 提供骨质疏松治疗咨询的医务人员应询问患者对双膦酸盐的基线了解程度。
- 医务人员可补充准确信息并纠正潜在的双膦酸盐误解。
研究设计与样本
- 描述性研究,用11个关于骨质疏松和双膦酸盐的检索词在4个搜索引擎中检索。
主要发现
- 最常描述的双膦酸盐益处是预防骨密度下降(77.1%的网站)。
- 最常描述的副作用是胃肠道问题(66.1%)和颌骨坏死(58.6%)。
- 多数网站未量化双膦酸盐益处(78.0%)或副作用(82.4%)。
- 补充与整合健康网站(P < .001)和药品诉讼网站(P < .001)较所有被编码网站更常偏向反对服用双膦酸盐。
- 一般医学知识网站较其他网站更平衡(P = .023)。
关键数值与推荐
- 美国预防服务工作组推荐在高风险人群中进行骨质疏松筛查并使用双膦酸盐治疗。
临床怎么用
- 提供骨质疏松治疗咨询的医务人员应询问患者对双膦酸盐的基线了解程度。
- 医务人员可补充准确信息并纠正潜在的双膦酸盐误解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Despite its effectiveness, bisphosphonate use for osteoporosis is low. We assessed bisphosphonate information on the internet and found the most commonly listed benefits/risks were bone density loss, gastrointestinal issues, and jaw necrosis, that risk quantification was rare, and information quality varied. Findings underscore the importance of clinical communication about bisphosphonates. INTRODUCTION: The US Preventative Services Task Force recommends osteoporosis screening and treatment with bisphosphonates in high-risk populations. However, bisphosphonate use among individuals with osteoporosis remains low. The content and quality of information from outside sources may influence individuals' bisphosphonate decisions. Therefore, we sought to assess the content and quality of osteoporosis treatment information available to the public by conducting an internet search and coding available bisphosphonate information. METHODS: Eleven search terms about osteoporosis and bisphosphonates were entered into four search engines. Two raters assessed websites for information about bisphosphonates, whether and how benefits and side effects were described and quantified, contraindications, and dosing instructions. Coders also assessed website interface and slant/balance of information. RESULTS: One thousand four hundred seventy-three websites were identified. Two hundred twenty-seven websites met inclusion criteria and were coded. The most common bisphosphonate benefit described was prevention of bone density loss (77.1% of websites). The most common side effects described were gastrointestinal problems (66.1%) and jaw osteonecrosis (58.6%). Most websites did not quantify bisphosphonate benefits (78.0%) or side effects (82.4%). Complementary/integrative health websites (p < .001) and pharmaceutical litigation websites (p < .001) were more often slanted against taking bisphosphonates, compared to all websites coded. General medical knowledge websites were more balanced than other websites (p = .023). CONCLUSIONS: The quality of bisphosphonate information on the internet varies substantially. Providers counseling patients about osteoporosis treatment should inquire about patients' baseline bisphosphonate knowledge. Providers can complement accurate information and address potential bisphosphonate misconceptions.
引用
- Fuzzell LN, Richards MJ, Fraenkel L, et al. What information can the lay public find about osteoporosis treatment? A descriptive study coding the content and quality of bisphosphonate information on the internet. Osteoporos Int. 2019. PMID: 31297567. doi:10.1007/s00198-019-05008-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。